论文部分内容阅读
目的:对糖尿病早期肾病患者进行降糖及厄贝沙坦和阿托伐他汀治疗,检测血和尿转化生长因子β1(TTGF-β1)水平,比较厄贝沙坦、阿托伐他汀以及两药联合治疗对早期DN患者TTGF-β2的影响。方法:选取糖尿病早期肾病患者65例,随机分为厄贝沙坦组、阿托伐他汀组、厄贝沙坦联合阿托伐他汀治疗组,选取29名健康体检者作为正常对照。12周后采用放射免疫法检测24h尿白蛋白排泄率(UAER),双抗体夹心酶联免疫吸附试验(ELISA法)检测血清和尿液TTGF-β1水平。结果:早期DN患者血和尿TTGF-β1水平显著高于健康志愿者(P<0.01)。与治疗前基础值相比,两药均能减少UAER以及血和尿中TTGF-β1(P<0.05),以联合治疗更为明显。结论:早期DN患者血和尿TTGF-β1水平升高,厄贝沙坦、阿托伐他汀以及厄贝沙坦联合阿托伐他汀能有效降低TTGF-β1,血和尿TTGF-β1水平可以作为DN早期诊断和治疗效果评估的有效指标。
OBJECTIVE: To treat patients with early diabetic nephropathy by hypoglycemic treatment and irbesartan and atorvastatin treatment, to detect the levels of serum and urinary transforming growth factor-β1 (TTGF-β1), to compare irbesartan, atorvastatin and two drugs Effect of combination therapy on TTGF-β2 in patients with early DN. Methods: Sixty-five patients with early diabetic nephropathy were randomly divided into irbesartan group, atorvastatin group and irbesartan combined with atorvastatin group, and 29 healthy subjects were selected as normal control. Twelve weeks later, the urinary albumin excretion rate (UAER) was measured by radioimmunoassay and the level of TTGF-β1 in serum and urine was measured by enzyme linked immunosorbent assay (ELISA). Results: The levels of TTGF-β1 in blood and urine in patients with early DN were significantly higher than those in healthy volunteers (P <0.01). Compared with the baseline before treatment, both drugs can reduce UAER and blood and urine TTGF-β1 (P <0.05), the combination therapy is more obvious. CONCLUSIONS: The levels of TTGF-β1 in blood and urine of patients with early DN are elevated. Irbesartan, atorvastatin and irbesartan combined with atorvastatin can effectively reduce the levels of TTGF-β1 and TTGF-β1 in blood and urine as DN early diagnosis and treatment of effective indicators to assess.